Complement Inhibitors for Intracerebral Hemorrhage Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for intracerebral hemorrhage (ICH) are limited, with a high mortality rate and lack of effective treatments beyond supportive care and surgery, necessitating the development of new therapies to address the inflammatory processes involved in brain injury.
Innovation Solution
Administration of a complement inhibitor to reduce or prevent C3a or C5a formation or activity, using specific inhibitors such as C5a inhibitors, C3aR inhibitors, or combinations thereof, to treat or prevent injury from intracerebral hemorrhage, which can be administered systemically or targeted to affected tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complement inhibition is used to reduce brain edema and inflammatory response, then neuroprotective effects are improved, but the lack of specificity makes it unclear which complement components are most relevant
Solution Approach 1:
The invention segments the complement system into specific targetable components (C3aR and C5aR receptors) rather than using broad complement inhibition. By developing selective antagonists for these specific receptors, the patent achieves precise targeting of the inflammatory pathway while avoiding off-target effects of non-specific complement inhibition.
Solution Approach 2:
The invention applies local quality by creating receptor-specific antagonists that target only the pathological inflammatory response mediated by C3aR and C5aR, while preserving other beneficial complement functions. This selective approach allows neuroprotection without the need to inhibit the entire complement system.
2Object-affected harmful factors
If broad complement inhibition is used, then edema formation is reduced, but the lack of specificity prevents identification of relevant complement components
Solution Approach 1:
The patent divides the complement system into discrete, targetable units (C3aR and C5aR receptors) and develops selective antagonists for each. This segmentation enables precise identification of which specific complement components are most relevant to ICH pathology, resolving the ambiguity of broad complement inhibition.
Solution Approach 2:
The invention changes the parameter of specificity by developing antagonists with high selectivity for C3aR and C5aR receptors. This parameter change allows precise measurement and identification of the role of specific complement components in edema formation and brain injury.
3Reliability
If C5 inhibition is used, then conflicting results are obtained regarding neuroprotection, indicating uncertainty in therapeutic efficacy
Solution Approach 1:
The patent segments the C5 pathway into its downstream effectors (C5a and C5aR) and develops selective C5aR antagonists. This segmentation allows for more consistent and reliable therapeutic effects by targeting the specific inflammatory mediator rather than the entire C5 pathway, reducing response variability.
Solution Approach 2:
The invention applies local quality by targeting specifically the C5aR-mediated inflammatory response rather than broad C5 inhibition. This selective approach produces more consistent neuroprotective effects by focusing on the specific pathological pathway while avoiding off-target effects that cause response variability.
Data Source
AI summary
Methods for treating or ameliorating the damage resulting from intracerebral hemorrhage are disclosed. The methods involve administration of a complement inhibitor to inhibit C3a or C5a formation or activity in the affected tissue. Pharmaceutical compositions suitable for use in the methods of the invention are also provided.